NetworkNewsBreaks – PreveCeutical Medical Inc. (
Post# of 77
(Total Views: 209)
Posted On: 04/16/2018 6:44:53 PM
NetworkNewsBreaks – PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Conducts Cannabinoid-based Sol-gel Product Research at University of Queensland
Health sciences company PreveCeutical Medical (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) recently announced the grant of three permits from the Australian government’s Department of Health that enable the importation of cannabis into Australia. The permits, which have been granted to the Pharmacy Australia Centre of Excellence (“PACE”) at the University of Queensland, will allow PACE to import cannabis plant material shipments for research purposes. An article discussing the company reads: “The intention of PreveCeutical is to apply its Sol-gel technology to cannabinoids for the development of therapies to relieve a variety of symptoms, including pain, inflammation, seizures and neurological disorders. The permits obtained by PACE will allow PreveCeutical to test various cannabis strains for the development and commercialization of cannabinoid-based Sol-gels. Sol-gels boast a variety of advantages over traditional liquid nasal sprays, offering longer therapeutic effects, lower dosage requirements and a reduction in irritation and other unwanted side effects.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Health sciences company PreveCeutical Medical (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) recently announced the grant of three permits from the Australian government’s Department of Health that enable the importation of cannabis into Australia. The permits, which have been granted to the Pharmacy Australia Centre of Excellence (“PACE”) at the University of Queensland, will allow PACE to import cannabis plant material shipments for research purposes. An article discussing the company reads: “The intention of PreveCeutical is to apply its Sol-gel technology to cannabinoids for the development of therapies to relieve a variety of symptoms, including pain, inflammation, seizures and neurological disorders. The permits obtained by PACE will allow PreveCeutical to test various cannabis strains for the development and commercialization of cannabinoid-based Sol-gels. Sol-gels boast a variety of advantages over traditional liquid nasal sprays, offering longer therapeutic effects, lower dosage requirements and a reduction in irritation and other unwanted side effects.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)PreveCeutical Medical Inc. (PRVCF) Stock Research Links
Scroll down for more posts ▼